Archive Newsletter
-
03.13.25 -- Frankly Fran: Subcutaneous Self-Administration: 3 Key Market Drivers, 3 Key Delivery Challenges
3/13/2025
03/13/25 Drug Delivery Leader Newsletter
-
03.10.25 -- Accelerating Antibody Delivery With Surf Bio's Bryan Mazlish
3/10/2025
03/10/25 Drug Delivery Leader Newsletter
-
03.04.25 -- Advancing Drug Design: Innovations In Bioavailability & Nanotechnology
3/4/2025
03/04/25 Drug Delivery Leader Newsletter
- Best of February: Top 5 Insights In Drug Formulation & Delivery 3/3/2025
-
03.03.25 -- Combination Products: Early-Stage Formulation, Device Considerations
3/3/2025
03/03/25 Drug Delivery Leader Newsletter
-
02.24.25 -- Integrating Development Processes For Combination Products
2/24/2025
02/24/25 Drug Delivery Leader Newsletter
-
02.17.25 -- Broadening The Range Of Self-Administered Biologics
2/17/2025
02/17/25 Drug Delivery Leader Newsletter
-
02.13.25 -- Frankly Fran: Use-Related Risk Analysis: Considering The FDA Guidance On URRA
2/13/2025
02/13/25 Drug Delivery Leader Newsletter
-
02.12.25 -- Superior Drug Delivery: High Drug Loads And Concentrations For Small And Large Molecules
2/12/2025
02/12/25 Drug Delivery Leader Newsletter
-
02.10.25 -- Defying Dysphagia Via Gel-Based Delivery
2/10/2025
02/10/25 Drug Delivery Leader Newsletter